Published in J Med Chem on January 01, 1991
Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci U S A (1995) 1.50
Synergistic Catalysis: A Powerful Synthetic Strategy for New Reaction Development. Chem Sci (2012) 1.30
Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci U S A (1993) 1.24
Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm (2010) 1.17
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer (2002) 1.05
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer (1996) 0.95
Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents. J Comput Aided Mol Des (1997) 0.91
Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemother Pharmacol (1994) 0.88
Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles. ACS Nano (2013) 0.85
Assessing the regioselectivity of OleD-catalyzed glycosylation with a diverse set of acceptors. J Nat Prod (2013) 0.84
Oral topoisomerase 1 inhibitors in adult patients: present and future. Invest New Drugs (1999) 0.84
FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatr Blood Cancer (2013) 0.82
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br J Cancer (2004) 0.82
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. Br J Cancer (2003) 0.81
Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin. Int J Pharm (2013) 0.80
Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. Br J Cancer (1999) 0.79
Topoisomerase I inhibitors and drug resistance. Cytotechnology (1998) 0.78
Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives. PLoS One (2011) 0.77
Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metab Dispos (2016) 0.77
Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives. ACS Med Chem Lett (2013) 0.77
MM3(96) parameterization for camptothecin analogs: an ab initio and molecular mechanics study. J Comput Aided Mol Des (1997) 0.76
A phase I and pharmacokinetic study of intraperitoneal topotecan. Br J Cancer (2001) 0.75
Synthesis and in vitro cytotoxic activity of chromenopyridones. Int J Med Chem (2012) 0.75
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene (1999) 3.23
Cytokine gene polymorphism in human disease: on-line databases. Genes Immun (1999) 2.86
Eukaryotic mRNA cap binding protein: purification by affinity chromatography on sepharose-coupled m7GDP. Proc Natl Acad Sci U S A (1979) 2.81
Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med (1983) 2.63
gamma Ray induced deoxyribonucleic acid strand breaks. 3' Glycolate termini. J Biol Chem (1983) 2.41
Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol (1993) 2.40
Isolation and identification of four cytokinins from wheat germ transfer ribonucleic acid. Biochemistry (1970) 2.30
Cytokinins: synthesis, mass spectra, and biological activity of compounds related to zeatin. Proc Natl Acad Sci U S A (1969) 2.30
Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ (1991) 2.20
Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A (1998) 2.18
Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. J Biol Chem (1994) 2.04
Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol Cell Biol (1991) 2.03
On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry (1989) 1.95
Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol (1988) 1.95
Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun (2001) 1.94
In-person vs telephone-administered multiple-pass 24-hour recalls in women: validation with doubly labeled water. J Am Diet Assoc (2000) 1.93
Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res (1979) 1.93
Structural basis of inhibitor selectivity in MAP kinases. Structure (1998) 1.89
A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see commetns]. Science (1998) 1.86
Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res (1980) 1.78
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res (1994) 1.75
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum (2000) 1.72
Cytokinin from soluble RNA of Escherichia coli: 6-(3-methyl-2-butenylamino)-2-methylthio-9-beta-D-ribofuranosylpurine. Science (1968) 1.66
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem (1987) 1.66
Longitudinal changes in fatness in white children: no effect of childhood energy expenditure. Am J Clin Nutr (1998) 1.64
Identification and quantitation of alditol acetates of neutral and amino sugars from mucins by automated gas-liquid chromatography. Anal Biochem (1971) 1.61
Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun (2007) 1.60
Influence of body composition on the accuracy of reported energy intake in children. Obes Res (2000) 1.59
Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem (1989) 1.57
Gel electrophoresis of mucous glycoproteins. I. Effect of gel porosity. Biochemistry (1971) 1.53
Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics (1997) 1.49
Gel electrophoresis of mucous glycoproteins. II. Effect of physical deaggregation and disulfide-bond cleavage. Biochemistry (1971) 1.46
Synthesis, tubulin binding, antineoplastic evaluation, and structure-activity relationship of oncodazole analogues. J Med Chem (1989) 1.43
Ribonucleoside phosphates via phosphorimidazolidate intermediates. Synthesis of pseudoadenosine 5'-triphosphate. Biochemistry (1973) 1.40
Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer (1977) 1.39
Diaminobenzidine as a myelin stain in semithin plastic sections. Biotech Histochem (1999) 1.38
Specificity of deoxyribonucleic acid cleavage by bleomycin, phleomycin, and tallysomycin. Biochemistry (1982) 1.36
Cytokinins: development of a potent antagonist. Proc Natl Acad Sci U S A (1971) 1.32
Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun (1999) 1.32
Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens (1997) 1.32
Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun (2002) 1.31
Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep (1978) 1.31
Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem (1997) 1.31
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Cross-finger pedicle flaps in the hand. J Bone Joint Surg Am (1971) 1.29
Developmental changes in energy expenditure and physical activity in children: evidence for a decline in physical activity in girls before puberty. Pediatrics (1998) 1.28
Increased monocyte cytokine production in association with systemic complications in acute pancreatitis. Br J Surg (1996) 1.28
Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer (1988) 1.27
Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia. Biochem Pharmacol (1978) 1.26
CYTOKININS: SYNTHESIS OF 6-(3-METHYL-3-BUTENYLAMINO)-9-beta-D-RIBOFURANOSYLPURINE (3IPA), AND THE EFFECT OF SIDE-CHAIN UNSATURATION ON THE BIOLOGICAL ACTIVITY OF ISOPENTYLAMINOPURINES AND THEIR RIBOSIDES. Proc Natl Acad Sci U S A (1968) 1.26
Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun (2006) 1.24
Identification of quantitative trait loci affecting reproduction in pigs. J Anim Sci (2001) 1.24
Analysis of products formed during bleomycin-mediated DNA degradation. Biochemistry (1985) 1.22
Cytokinin of wheat germ transfer RNA: 6-(4-hydroxy-3-methyl-2-butenylamino)-2-methylthio-9-beta-D-ribofuranosylpurine. Science (1969) 1.22
The isolation and identification of two cytokinins from Escherichia coli transfer ribonucleic acids. Biochemistry (1969) 1.22
On the "activation" of cytokinins. J Biol Chem (1975) 1.22
Anatomical course of the thenar branch of the median nerve--usually in a separate tunnel through the transverse carpal ligament. J Bone Joint Surg Am (1970) 1.19
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst (1989) 1.19
"Chemical aminoacylation" of tRNA's. J Biol Chem (1978) 1.19
The effect of "cap" analogs on reovirus mRNA binding to wheat germ ribosomes. Evidence for enhancement of ribosomal binding via a preferred cap conformation. J Biol Chem (1978) 1.18
Metal ion and substrate structure dependence of the processing of tRNA precursors by RNase P and M1 RNA. J Biol Chem (1990) 1.17
A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics (1995) 1.17
Plakortides, novel cyclic peroxides from the sponge Plakortis halichondrioides: activators of cardiac SR-CA(2+)-pumping ATPase. J Nat Prod (1996) 1.17
Oligonucleotide N-alkylphosphoramidates: synthesis and binding to polynucleotides. Biochemistry (1988) 1.16
Chemical transformations of 7,9-disubstituted purines and related heterocycles. Selective reduction of imines and immonium salts. J Org Chem (1976) 1.16
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst (1992) 1.16
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. Cancer Res (1976) 1.16
In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep (1978) 1.15
T4 RNA ligase mediated preparation of novel "chemically misacylated" tRNAPheS. Biochemistry (1984) 1.15
Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. Genes Immun (2007) 1.14
Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res (1988) 1.13
Site-specific cleavage of RNA by Fe(II).bleomycin. Proc Natl Acad Sci U S A (1990) 1.13
DNA sequence specificity of the pyrrolo[1,4]benzodiazepine antitumor antibiotics. Methidiumpropyl-EDTA-iron(II) footprinting analysis of DNA binding sites for anthramycin and related drugs. Biochemistry (1986) 1.12
Transport of antimicrobial agents using peptide carrier systems: anticandidal activity of m-fluorophenylalanine--peptide conjugates. J Med Chem (1983) 1.11
N 6 -( 2 -Isopentenyl)adenosine: the regulatory effects of a cytokinin and modified nucleoside from tRNA on human lymphocytes. Biochim Biophys Acta (1972) 1.11
Chemistry of the alkali-labile lesion formed from iron(II) bleomycin and d(CGCTTTAAAGCG). Biochemistry (1988) 1.09
Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res (1987) 1.09
Sequential expression of transforming growth factors alpha and beta 1 by eosinophils during cutaneous wound healing in the hamster. Am J Pathol (1993) 1.08
The pronator quadratus in motions and in stabilization of the radius and ulna at the distal radioulnar joint. J Hand Surg Am (1976) 1.08
Metabolites of methyl 5(6)-butyl-2-benzimidazolecarbamate (parbendazole). Structure and synthesis. J Med Chem (1973) 1.08
In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res (1989) 1.08
Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg Med Chem Lett (1998) 1.07
Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res (1985) 1.07
Fat intake and adiposity in children of lean and obese parents. Am J Clin Nutr (1996) 1.06
Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg Med Chem Lett (2001) 1.05
The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment. Eur J Immunol (1989) 1.05
Biological responses to porcine respiratory and reproductive syndrome virus in pigs of two genetic populations. J Anim Sci (2005) 1.05